Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00274443 | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin | PHASE2 | COMPLETED | 250 | — | — | Mar 1, 2005 | Jun 1, 2007 | Nov 12, 2019 | 1 | Russia |
| Arm | Type | Description |
|---|---|---|
| ABI-007 and Carboplatin | EXPERIMENTAL | ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer. |
| Name | Type | Description |
|---|---|---|
| ABI-007 (Abraxane) and Carboplatin | DRUG | ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks |
Inclusion Criteria: * Histologically or cytologically confirmed NSCLC Stage IIIB with pleural effusion or evidence of inoperable local recurrence or metastasis (Stage IV). * Male or non-pregnant and non-lactating female, and ≥ 18 years of age. ( )If a female patient is of child-bearing potential, a...